Background: Cancer-associated muscle wasting (CAW), a symptom of cancer 2 cachexia, is associated with approximately 20% of lung cancer deaths, and 3 remains poorly characterized on a mechanistic level. Current animal models for 4 lung cancer-associated cachexia are limited in that they: 1) primarily employ flank 5 transplantation methods, 2) have short survival times not reflective of the patient 6 condition, and 3) are typically performed in young mice not representative of 7 mean patient age. This study investigates a new model for lung cancer-8 associated cachexia that can address these issues and also implicates muscle 9 regeneration as a contributor to CAW. 10
INTRODUCTION 28
Cancer cachexia is a complex syndrome associated with approximately 20% of 29 lung cancer deaths; a hallmark symptom of cancer cachexia is cancer-associated 30 muscle wasting (CAW) [1, 2] . Although this syndrome is associated with negative 31 patient outcomes, it remains poorly understood on a mechanistic level. Many 32 groups have investigated the inflammatory environment associated with CAW, in 33 particular, inflammatory cytokines such as tumor necrosis factor alpha (TNFa) 34 and interleukin 6 (IL6). Despite considerable time invested in this area, clinical 35 trials targeting the inflammatory microenvironment alone have been unsuccessful 36 [3, 4] . Other groups have focused on the proteolytic environment in muscle, as a 37 potential driver of CAW, implicating both autophagy and ubiquitin-mediated 38 pathways as potential drivers of CAW [5] [6] [7] . The current mechanistic 39 understanding of CAW is largely based off of work done in mouse models, most 40 notably the Lewis lung carcinoma (LLC) and C-26 models. 41
The LLC model of CAW relies on transplantation of LLC1 non-small cell lung 42 cancer cells, derived from C57/B6 mice, into syngeneic, and thus 43 immunocompetent, C57/B6 recipient mice. The LLC model is one of the few 44 syngeneic and reproducible models for lung cancer/lung-cancer associated 45 wasting available today [8] . Most commonly, LLC1 cells are implanted via flank 46 injection, which results in large primary tumors around 7 days post implantation. 47 A second popular model for CAW, the C26 model, was first described in 1990 48 and utilizes flank injection of colon 26 carcinoma cells [9] . Like the LLC model, 49 this model displays elevated expression of proteasome components, which 50 contribute to loss of muscle mass [10] . The C26 model presents with longer 51 median survival (25 days) than the LLC model [10] . Notably, both the C26 and 52 LLC models share a common weakness in that tumors do not arise in the tumor 53 tissue of origin. Although recent studies have attempted to correct this issue 54 using autochthonous genetically engineered mouse models (GEMMS), their 55 utility and flexibility are limited. For example, in pancreatic cancer, there have 56 been multiple efforts to create CAW models that focus on tumors arising in their 57 native tissue via either genetic manipulation or orthotopic implantation [11] [12] [13] [14] [15] . 58
The benefits and limitations of these models are addressed in more depth in the 59 discussion. Despite these advances in the context of pancreas cancer, lung 60 cancer models have lagged behind. Orthotopic transplantation has been 61 established in rodent models, but requires an invasive surgery [16] [17] . 62
Furthermore, genetic methods to derive orthotopic tumors in lungs require viral 63 delivery of Cre recombinase [18] . Complications arising in both these models are 64 high and prompted us to develop a simple, reproducible, and scalable model of 65 lung CAW. 66
We identified the need for better models of CAW that met the following criteria: 1) 67 immunocompetent environment, 2) tumors arising in the appropriate/matching 68 tissue of origin, and 3) ability to modulate the timing/duration of wasting. Here, 69
we present studies on a novel mouse model for lung CAW, which has met these 70 criteria. This model utilizes syngeneic, immunocompetent mice and tail-vein 71 injection of cells as a modality for lung tumor seeding; shows a median survival 72 of approximately 26 days that can be modulated as a function of injected cell 73 number; and exhibits hallmarks of lung CAW. The model presented herein fills a 74 gap in models for studying CAW, and will be a valuable resource for the wasting 75 community moving forward. 76
RESULTS 77
Development of a transplantable model for lung cancer-associated tissue loss 78
Given the increasing need in the CAW field for models featuring tumors arising in 79 their natural location, we sought to develop such a model in the context of lung 80 cancer. To accomplish this, we used tail vein injection as a method whereby 81 injected lung tumor cells implant primarily in the lungs [19] . Cells were derived 82 from a murine lung adenocarcinoma and cultured more than 10 passages prior to 83 injection. Cells were suspended in PBS for the injection and control animals were 84 injected with PBS vehicle only. Throughout the course of the study we assessed 85 body composition via magnetic resonance imaging (MRI) until humane endpoint 86 (see experimental schematic in Figure 1A) . We performed survival studies on 3 87 cohorts of mice (total n=10 vehicle and 15 tumor) and observed significantly 88 decreased survival for tumor bearing mice (average survival tumor=26.2 days) 89 ( Figure 1B) . Upon macroscopic inspection of the lungs, tumor bearing mice had 90 many small nodules, fibrotic tissue, and increased tissue density (Figure 1C) . 91
Upon microscopic inspection of the lungs in tumor-bearing mice, alveolar fields 92 were replaced by multiple, coalescing tumor nodules (>70% in 3 animals, 40-93 50% in 2 animals assessed). The tumor nodules consisted of loosely packed, 94 vacuolated cells and in some cases were associated with small clusters of intra-95 tumoral lymphocytes, usually at the margins of blood vessels or nodules. Lastly, 96 the pleural surface was roughened by projecting fronds / plaques of tumor cells. 97
In comparison, vehicle animals displayed expanded alveolar spaces and a 98 smooth pleural surface ( Figure 1D) . Furthermore, we observed a statistically 99 significant increase in total lung weight in tumor-bearing mice (Figure 1E) . 100
Concurrent with evaluations of tumor effects on overall survival, we performed 101 longitudinal body composition analyses. First, we observed a significant 102 difference in time and treatment co-variance for body weight, which was 103 highlighted by significant decreases in body weight at 10, 14, and 17 days post 104 tumor implantation ( Figure 1F) . Next, we observed a significant difference in time 105 and treatment co-variance for total fat mass, which was highlighted by significant 6 decreases in fat mass at 14, 17, and 21 days post tumor implantation ( Figure  107 1G). Lastly, we observed a significant difference in time and group co-variance in 108 total lean mass, although individual days had no significant difference ( Figure  109 1H). Overall, there were decreases in total body weight, total fat mass, and total 110 lean mass as the tumor progressed (the latter two measured by MRI) (Figure 1F -111 H). 112
Lung cancer-associated inflammation 113
Loss in both body weight and lean mass are hallmarks of CAW. Many studies 114
have implicated heightened inflammatory signaling as a driver of CAW [20] [21] [22] . 115
We quantitatively assessed concentrations of 31 cytokines in the serum of tumor-116 bearing and vehicle animals (EveTechnologies) (n=5 vehicle and 4 tumor). 117
Ranked analysis (vertically by their average in the tumor-bearing animals; 118 highest to lowest) revealed substantial differences between experimental groups 119 (Figure 2A) . Specifically, we observed significant differences in 4 factors: 120
Eotaxin (down~2 fold), C-X-C motif chemokine 5 (LIX, down ~10 fold), TNFa (up 121 ~30 fold) and vascular endothelial growth factor (VEGF, up ~190 fold) ( Figure  122 2C). Of note, TNFa accumulation has been previously implicated in CAW [20, 123 23] . 124
Lung cancer-associated muscle loss 125
Considering both the loss of lean mass by MRI analysis and the accumulation of 126 classical markers of CAW in the serum, we next performed a histological and 127 molecular assessment of skeletal muscle. First, we assessed tibialis anterior (TA) 128 muscle cross sections by immunofluorescent staining for laminin, a marker of 129 myofiber membranes, and DAPI (nuclei) ( Figure 3A) . Minimum feret diameters 130 were measured, compiled, and calculated using myovision (mean feret diameter: 131 3 million = 40.4 um, vehicle = 44.4 um, and found a statistically significant 132 decrease in the non-linear regressions fit to the histograms of minimum feret 133 diameter distribution of tumor-bearing mice (Figure 3B ) [24] . Additionally, we 134 observed a significant decrease in TA weight in tumor bearing animals; this was 135 not due to a reduction in the total number of myofibers in the TA of these animals 7 ( Figure 3C-D) . Since we observed a reduction in myofiber size, but not total 137 number of myofibers, we postulated that this could be due to a decrease in the 138 regenerative capacity of muscle. Using immunofluorescent staining, we queried 139 the number of Pax7 positive muscle progenitor cells. We observed a statistically 140 significant increase in Pax7 positive cells per millimeter squared of tissue ( Figure  141   3E ). Additionally, we assessed the number of centrally located nuclei (CLN), 142 which mark actively regenerating myofibers containing recently fused muscle 143 progenitor cells. We did not see any difference in the number of CLN per 144 millimeter squared of tissue between vehicle and tumor-bearing mice ( Figure  145 3F). Lastly, to acquire a molecular understanding of regenerative capacity of 146 muscle from tumor-bearing animals, we used quantitative RT-PCR to measure 147 several transcripts associated with early myogenesis, late myogenesis/fusion, 148 and muscle atrophy. Visualized in a heat map, we see a trend toward higher 149 expression of atrophy transcripts (Trim63 and Fbxo32) and early makers of 150 myogenesis (Pax7 and Myod1), and lower expression of late markers of 151 myogenesis (Figure 3G) . 152
Transplanted cell number correlates with survival and CAW progression 153
Upon establishing that our lung cancer model induces loss in total body weight, 154 lean mass, and is also associated with an impaired muscle regeneration 155 phenotype, we sought to determine if survival time/CAW progression could be 156 experimentally modulated. To accomplish this, we varied the number of cells 157 injected as follows: 3 million cells (used in all previous figures), 1 million cells, 158 300,000 cells, and vehicle. We also tested 30,000 and 3,000 cells but found 159 inconsistent inoculation of tumors and omitted these groups from further study 160 (data not shown). We assessed survival of animals in each group and found that 161 lowering the number of cells injected prolonged survival as evidenced by a 162 statistical increase in survival from 3 million to 1 million cells (p=0.0208), 1 million 163 to 300,000 cells (p=0.0024), and 300,000 cells to vehicle (p=0.0046) ( Figure 4A-164   B ). We also observed changes in lung condition, as evidenced by increased lung 165 weight in 3 and 1 million injected cells, and macroscopic changes in lung 166 condition similar to those observed previously (Figure 4C-D) . 167
We next performed body composition and muscle morphometrics analyses in 168 mice receiving variable numbers of tumor cells. As before, we observed 169 decreasing trends in body mass, lean mass and fat mass in tumor bearing mice 170 of all groups (Figure 5A-C) . Specifically, we observed significant difference in 171 time and treatment co-variance for body weight, in 3 million, 1 million, and 172 300,000 implanted cell groups compared to vehicle (Figure 5A) . We also 173 observed significant difference in time and treatment co-variance for total lean 174 mass in 3 million and 1 million implanted cell groups compared to vehicle ( Figure  175 5B). In lower implantation doses, we did not observe significant differences in 176 total fat mass. Because tumors were restricted primarily to the lungs (with the 177 exception of some metastases) ( Table 1) , it was not possible to discount tumor 178 mass from MRI measurements. Evaluation of TA muscles from tumor-bearing 179 mice revealed statistically decreases in TA mass in the 300,000 cells group, 180 similar to the 3 million cells group (Figure 5D) . Additionally, myovision-based 181 assessment of minimum feret diameters revealed increasingly significant 182 decreases as the cell injection number decreased (mean feret diameter: 1 million 183 = 41.3 um, 300,000 = 32.6 um, vehicle = 44.4 um)( Figure 5E ). 184 185 9
DISCUSSION 186
In order to gain a more thorough understanding of CAW, there is a need for 187 models that more accurately capture the patient condition. This new and novel 188 model for CAW meets several needs in the field such as: 1) immunocompetence 189 With regard to points two through four, developing therapeutics for CAW is 197 ultimately dependent on mouse models that reflect the complex molecular nature 198 of this syndrome. We showed that this model exhibits an inflammatory signature 199 similar to published signatures of CAW patients [20, 21, [28] [29] [30] . Additionally, our 200 model supports numerous studies linking both elevated catabolism and impaired 201 skeletal muscle regeneration as contributors to 31] . Our observation 202 that there is an accumulation of Pax7+ cells in the TA muscle, but no change in 203 the number of centrally located nuclei may be indicative of increased progenitor 204 cell expansion, with failure to incorporate into the damaged/cachectic muscle. 205
Although we probed genes related to fusion and progenitor cell maturation by 206 qPCR and did not observe differences in expression, a more detailed 207 assessment of the progenitor cell population would be necessary to make 208 definitive conclusions about suppressed muscle regeneration in this model. 209
A major weakness of many CAW mouse models is the age of wasting onset. 210
Genetic models, such as the KPC model, are predisposed to spontaneously 211 develop tumors, which gives investigators little control over the age of onset. 212
With cachectic cancers affecting a primarily elderly population, it is critical that 213 new models are able to account for this confounding factor. For pancreatic 214 cancer, this problem has largely been solved by the KPP mouse, which 215 expresses pancreas-specific oncogenes under Cre recombinase control [13] . 216
However, for lung cancer, this is only beginning to be addressed [15] . Although 217 our model has not yet been adapted for use in aged mice, the transplantable 218 nature of the model permits use in any age of animal. Our model has the added 219 attraction that it does not require a major surgery or viral infection, which could 220 affect inflammatory status, making it more amenable for aged animals with higher 221 frailty than young animals [32] . 222
The lack of CAW models that accurately assess the effects of age highlights a 223 second issue, which is the difference between muscle atrophy and the absence 224 of growth. A primary concern with the KPC pancreatic cancer mouse model is 225 that these mice are significantly smaller than littermate controls prior to palpable 226 tumor development. This suggests that fetal expression of the oncogenes is 227 contributing to impaired muscle development [13] . Although spontaneous genetic 228 models, such as the KPC model, are dramatic examples of the difference 229 between atrophy and absence of growth, this principle implicates many 230 transplantation models [33] . Even in the study presented here, with age-matched 231 controls, it is evident that mice in the 3-6 month age group are still growing 232 (gaining total body weight and fat mass). Although muscle development is 233 typically considered complete at 3 months and lean mass is essentially stabilized 234 in our animals, this anabolic state is unrepresentative of the patient population 235 [13, 34, 35] . The model presented here is amenable to assessing CAW in aged 236 animals (greater than one year), which may lead to a better understanding of 237 CAW mechanisms and more efficient translatability to the clinic. 238
Another aspect of the patient condition poorly modeled in rodents is the severity 239 and duration of wasting symptoms. Recently, it was established that the cachexia 240 syndrome could be divided into three clinical stages: pre-cachexia, cachexia, and 241 refractory cachexia. Although refractory cachexia is marked by a short (only three 242 months) survival, wasting is present for much longer -an important observation 243 that is difficult to study in rapidly progressing rodent CAW models. Importantly, 244 with respect to intervention, some suggest that it is in the earlier stages (non-245 refractory) that therapeutics may be more effective [36] . Despite these features in 246 patients, mouse models like LLC and C26 have rapid symptom onset and short 247 survival times. Failing to capture the earlier stages of cachexia is likely a 248 contributor to the failed clinical trials based on pre-clinical data derived using 249 these models. The ability of our model to be titrated by cell dosage provides an 250 important opportunity explore the timing and duration of wasting symptoms more 251
thoroughly. 252
Despite the many strengths highlighted in this study, the model presented herein 253 does have limitations. Perhaps the most notable limitation is one common to all 254 orthotopic lung cancer models, which is the difficulty for assessing tumor burden 255 in living animals. This could be remediated by stably transfecting cells with a 256 fluorescent reporter and utilizing in vivo imaging modalities. Additionally, in some 257 cohorts, we observed high levels of metastasis outside the thoracic cavity. This 258 may be representative of patients that exhibit metastases, but also complicates 259 data interpretation. Nevertheless, the model presented here is an important step 260 forward as CAW research progresses and will be a valuable resource for future 261 research aimed at understanding the etiology of lung cancer-associated muscle 262 and fat wasting. were euthanized when endpoint criteria (weight loss greater than or equal to 20% 392 of body weight, inability to ambulate, inability to reach food and/or water, tumors 393 greater than or equal to 10% of body weight, tumors that have ulcerated, a body 394 condition score of 1 or less using the IACUC approved scoring system) was 395
reached. Blood serum, heart muscle, lungs, tibialis anterior (TA), gastrocnemius 396 (GR) and epididymal fat pad were collected immediately for analyses. Exact n for 397 each experiment included in the figure legends. 398
Animal imaging 399
Body weight, lean mass, and fat mass were measured twice weekly until 400 endpoint. A baseline measurement was taken prior to start of study. Body 401 composition was measured using magnetic resonance imaging (EchoMRI-402 100/130) system, EchoMRI, Houston, TX, USA). 403
Cell culture 404
393P cells were grown on tissue culture treated dishes in growth media 405 consisting of DMEM media (Gibco #11995-065, lot 2051518) supplemented with 406 10% fetal bovine serum (Gibco #10099131, lot 2017488) and antibiotics. Cells 407 were validated by IDEXX analytics and confirmed to be a pure culture and 408 20 murine in origin. Cells were removed from plate with TrypLE (Gibco, 12604-013), 409 counted, and resuspended in PBS prior to injection. 410
Immunostaining 411
Left TA whole muscle was prepared for O.C.T embedding and cryosectioned. 412
Tissue sections (8-10um) were post-fixed in 4% paraformaldehyde for 5 minutes 413 at room temperature prior to immunostaining. Once fixed, isolated tissue 414 sections were permeabilized with 0.5% Triton-X100 in PBS, followed by blocking 415 with 3% BSA in PBS. Primary antibody incubations occurred at RT for 90 416 minutes or overnight in 4 degrees, and secondary antibody incubations followed 417 at RT for 45 minutes in 3% BSA in PBS. The following antibodies were used in 418 this study: Laminin (Sigma 4HB-2) and Pax7 (developmental hybridoma bank). 419
Secondary antibodies were all Alexa fluorescent conjugates (488, 555, or 
Statistics 449
Data are represented as the mean ± SD using GraphPad Prism (GraphPad 450 Software, San Diego, CA) unless noted otherwise in the figure legends. 451 Quantification of muscle cross sections using minimum feret diameter 452 measurements was analyzed by non-linear regression (least squares method) 453 and compared between conditions using an extra-sum-of-squares F test. All 454 other comparisons between groups were performed using unpaired two-tailed 455 student's t tests or mixed-effects analysis, as noted in figure legends. For all 456 analyses, a p<0.05 was considered significant (denoted with *) 457
Data availability 458
Datasets generated during the current study are available from the 459 corresponding author upon request. 
